Cancer Advisor

Lung cancer remains one of the leading causes of cancer-related deaths worldwide, but 2025 has brought remarkable progress in immunotherapy, transforming treatment landscapes for both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Drawing from recent clinical trials, conferences like ASCO, AACR, and ELCC, and emerging real-world data, this guide highlights key breakthroughs. We'll focus on evidence-based advances, including checkpoint inhibitors, combination therapies, novel vaccines, and targeted immunotherapies, with practical insights for patients and caregivers. Immunotherapy Fundamentals in Lung Cancer Immunotherapy harnesses the body's immune system to target cancer cells, often via checkpoint inhibitors like PD-1/PD-L1 blockers (e.g., pembrolizumab, nivolumab). In 2025, these are increasingly combined with chemotherapy, targeted drugs, or other modalities for better outcomes. For NSCLC, which accounts for about 85% of cases, immunotherapy has beco...

Abstract Background: Metastatic triple-negative breast cancer (mTNBC) is an aggressive malignancy with poor prognosis. Immune checkpoint inhibitors (ICIs) have improved outcomes but remain limited. Repurposing antiparasitic agents ivermectin and mebendazole, supplemented by vitamin D3 and high-bioavailable curcumin, may enhance antitumor immunity and survival. Methods: We simulated a double-blind randomized controlled trial (RCT) enrolling 10,000 mTNBC patients (5,000 per arm) over 5 years. Experimental arms received high-dose ivermectin, mebendazole, pembrolizumab or balstilimab, vitamin D3 (5,000 IU daily), and high-bioavailable curcumin; controls received ICIs alone. We modeled three improvement scenarios including optimized antiparasitic dosing, dual checkpoint blockade with tumor microenvironment (TME) modulators, and biomarker-guided patient selection plus enhanced supportive care. Efficacy endpoints included objective response rate (ORR), progression-free survival (PFS), ove...

Twice, Jim Mann survived aggressive melanoma, which quickly kills most people. Surgery in 2016 to remove a large spot on his head—along with lymph nodes, some under his skull—was sufficient to put Mann into remission, surprising doctors who expected to find the cancer had spread throughout his body. Eighteen months later, follow-up testing on a mass he found revealed eight tumors throughout his body. However, two months into his two-year immunotherapy treatment protocol, the tumors disappeared. His immune system, which he described as good before his diagnosis, responded robustly to treatment. By then, he had also quit eating sugar, minimized stress, and joined a support group. “I shouldn’t have lived more than a month or two, based on how big the melanoma was, but I’m glad they didn’t tell me that at the beginning,” Mann told The Epoch Times. “The fact that they were shocked every time they saw me was unnerving, but great at the same time.” Under ideal conditions, the immune system is...

Abstract Background: Fenbendazole and mebendazole, benzimidazole antiparasitic drugs, have been investigated for repurposing in oncology due to preclinical antitumor effects. This systematic review synthesizes evidence from PubMed and related sources on their roles in cancer, including mechanisms, efficacy, and clinical data up to August 2025. Methods: Comprehensive searches on PubMed used "fenbendazole AND cancer" (~50 results) and "mebendazole AND cancer" (~300 results). Filters for systematic reviews yielded none dedicated; clinical trials were limited. Web searches supplemented for reviews and trials (2024-2025). Inclusion: studies on anticancer effects; exclusion: non-cancer uses. Narrative synthesis due to heterogeneity and lack of meta-analyzable R CTs. Results: Preclinical studies (n≈300 combined) show antitumor activity in cancers like colorectal, breast, ovarian, and lung via microtubule disruption, apoptosis, and oxidative stress. Mechanisms include RO...

Abstract Background: Ivermectin, an established antiparasitic agent, has shown promising anticancer properties in preclinical studies. This systematic review synthesizes the current evidence from PubMed and related databases on ivermectin's role in cancer, including mechanisms, preclinical efficacy, and limited clinical data up to August 2025. Methods: A comprehensive search was conducted on PubMed using the terms "ivermectin AND cancer," yielding 390 results. Additional searches filtered for systematic reviews (0 results) and clinical trials (0 dedicated results in PubMed, but emerging trials identified via ClinicalTrials.gov and web sources). Web searches targeted reviews and trials from 2024-2025. Inclusion criteria: studies on ivermectin's anticancer effects; exclusion: non-cancer applications (e.g., COVID-19). Data were narratively synthesized due to the absence of meta-analyzable clinical trials. Results: Preclinical studies dominate (n≈350), demonstrating i...